×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Innovative Direct-to-Patient Study Model to Capture PRO Instrument Validation Data for Submission to a Regulatory Authority
Session Chair(s)
April N. Naegeli, DrPH, MPH
Senior Research Scientist, Global Patient Outcomes and Real World Evidence
Eli Lilly and Company, United States
This session will discuss benefits and limitations associated with using a direct-to-patient model for observational research. In addition, we will present learnings from our experience using a direct-to-patient model for patient-reported outcome (PRO) instrument validation.
Learning Objective : Review the strategic approach to using an innovative research model for validating a patient-reported outcome measure; Evaluate benefits and limitations associated with implementing a novel direct-to-patient approach to conducting this type of observational study; Define advantages of integrating multiple technologies and rapidly implementing lessons learned to maintain patient engagement.
Speaker(s)
Strategic Approach to Using an Innovative Research Model for Validating a Patient-Reported Outcome Measure
April N. Naegeli, DrPH, MPH
Eli Lilly and Company, United States
Senior Research Scientist, Global Patient Outcomes and Real World Evidence
Benefits and Limitations Associated With Implementing a Novel Direct-to-Patient Approach to Conducting a Validation Study
John Reites
THREAD, United States
Chief Executive Officer
Advantages of Integrating Multiple Technologies and Rapidly Implementing Lessons Learned to Maintain Patient Engagement
Brandon M. Wojtowicz
ERT, United States
Project Manager, eResearch Technology
Have an account?